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Background
Yaws is a bacterial infection causing lesions in the skin and 
bones, primarily found in tropical areas. It is caused by the bac-
teria Treponema pallidum pertenue, and spread by skin to 
skin contact with an infected lesion. While the initial lesion 
(“mother yaw”) may spontaneously heal without treatment, 
the individual remains infected and relapses to infectious 
yaws represent a reservoir of future infection. Such relapses 
can occur up to 10 years later, and symptoms deteriorate with 
additional relapses. Without treatment, progression to second-
ary and tertiary yaws can result in chronic disfigurement and 
disability. It is critical, therefore that any eradication strat-
egy must successfully treat asymptomatic as well as infectious 
individuals.
Efforts to eradicate yaws in the 1950s used injections of 
benzylpenicillin to successfully reduce worldwide cases by 95% 
(Mitjà et al., 2015). However, limited surveillance and resources 
unfortunately lead to resurgence in West Africa, Asia and the 
Pacific in the 1970s (Asiedu et al., 2014). Renewed eradication 
efforts began in 2012, when a single dose of oral azithromycin 
was shown to be non-inferior to injection with benzylpenicil-
lin (Mitjà et al., 2012). In 2016 India became the first coun-
try to be declared by the World Health Organization (WHO) to 
be free of yaws.
Current eradication efforts follow the Morges strategy (World 
Health Organization, 2012), which recommends one or more 
rounds of total community treatment (TCT) followed by rounds 
of total targeted treatment (TTT), in which active cases and 
their contacts (household, frequent family friends, schoolmates 
and playmates) are treated. TTT is intended to ensure treatment 
of asymptomatic non-infectious individuals (latent infections), 
who can later relapse to infectious yaws. Azithromycin is effec-
tive in over 95% of cases, with intramuscular benzathine 
penicillin used as a second line treatment where necessary.
The WHO is currently developing the 2030 neglected tropi-
cal diseases (NTDs) Roadmap, detailing the goals for each dis-
ease and the strategies that should be used to reach these goals. 
Two rounds of consultations with endemic countries, partners, 
donors and other stakeholders were held to refine the proposed 
targets. The goal for yaws is to certify all member states 
free of yaws transmission by 2030, with 50% certified by 2023 
and 70% by 2025 (World Health Organization, 2019). In this 
letter we discuss the insights gained from modelling work to 
date, the feasibility of the proposed goals and the strategies 
required to reach them.
Mathematical modelling of yaws transmission
The mathematical modelling of yaws transmission is still 
in its early days, comprising just seven papers that include 
modelling (Dyson et al., 2018; Fitzpatrick et al., 2014; Fitzpatrick 
et al., 2018; Gart & De Vries, 1966; Marks et al., 2017; Mooring 
et al., 2019; Mushayabasa et al., 2012) and a single exam-
ple fitting a simple catalytic model to age structured yaws data 
(Muench, 1959). While some work comprises mostly theoretical 
research (Gart & De Vries, 1966; Mushayabasa et al., 
2012), more recent publications have used economic or 
transmission modelling to consider questions regarding the 
funding and implementation of eradication programmes.
The costs of yaws eradication
Economic modelling undertaken by Fitzpatrick et al. (2014) 
revealed a high degree of uncertainty in the cost of eradi-
cation, costing USD 362 (75-1073) million in 12 endemic 
countries and USD 324 (47-522) million per disability-adjusted 
life year. This is calculated using a compartment model with 
primary, secondary and tertiary infection with gradual exit 
of the at risk population due to poverty reduction. There are many 
uncertain quantities in this calculation due to lack of data regard-
ing the cost of TTT (here assumed to be 30-50% of the cost of 
TCT), lack of disability weights for early or late-stage yaws 
(DALYs were calculated using weights for comparable condi-
tions) and uncertainties around the population at risk and the 
unit costs of delivery in different countries.
Campaign strategies: TCT vs TTT
Two recent papers focussed on the feasibility of reaching eradi-
cation by the current strategy, and ways to determine how 
many rounds of TCT and TTT will be required. The first uses a 
stochastic model of community-level yaws transmission, and 
determined that to reach 80% probability of achieving eradica-
tion using 8 rounds of twice-yearly treatment (3 rounds of TCT 
followed by 5 rounds of TTT) 80% coverage in low transmis-
sion (R0 = 1.45) settings, and 95% coverage in high transmission 
(R0 = 2.47) settings was required (Marks et al., 2017). 
Here TTT is modelled as having the potential to achieve 
different coverage levels in active and latent yaws. If only one 
round of TCT was conducted then 90% coverage was required, 
followed by 5 rounds of TTT at 90% coverage of active infec-
tions and 65% coverage of latent infections. In high transmis-
sion settings with yearly treatment no combination of variables 
or treatments achieved elimination of transmission (EOT) in the 
Marks et al. model.
A second paper used household model of infection, param-
eterised using data from the Solomon Islands, and indicated 
that latent infections are often not co-located in the same house-
holds as clinical infections. This would imply that treating 
clinical cases and their household contacts would miss a large 
fraction of latent infections (Dyson et al., 2018). This work 
inferred the infection statuses of adults, for whom serological 
tests were not conducted and found that between 65% and 
100% of latent infections were in households without a clini-
cal infection present. The conclusion that latent infections 
are not closely connected to active cases is also supported by 
empirical studies showing that there may be as many as 6–10 
latent cases for each active yaws case (Marks et al., 2015) 
Page 3 of 9
Gates Open Research 2019, 3:1576 Last updated: 12 DEC 2019
and that in an implementation study of the Morges strategy 
(Mitjà et al., 2015) the ratio of latent:active cases increased 
following several rounds of treatment suggesting that the 
intervention (single round of TCT followed by only TTT) 
was more effective at treating active cases than latent cases. 
Since latently infected individuals may relapse to infec-
tious yaws as many as 10 years later, this represents a signifi-
cant reservoir of infection. Indeed, even the time to relapse is 
uncertain, so that it is unclear how long it is necessary to 
observe zero cases for before we can be certain of elimination. 
Note that in the household model, even with 100% coverage 
of active cases, household-based TTT would achieve a maxi-
mum coverage in latent infections of 35% (Dyson et al., 2018), 
far below the 65% coverage of latent infection required in 
the Marks et al. model.
A recent stochastic compartmental metapopulation model con-
structed by Mooring et al. (2019) also examined the perform-
ance of TCT vs TTT in reducing the prevalence of both active 
and latent yaws. The model simulated yaws transmission and 
intervention in populations averaging 20000 people divided 
among 200 “hamlets” that ranged in size from 75 to 125 people. 
In view of the finding from other modelling studies that a house-
hold definition of contact may be inadequate, the model of 
TTT assumed that cases of active disease were detected with 
a probability of 90% and that treatment was administered to, 
on average, 90% of all persons living in any hamlet with at 
least one detected active case. The model assessed the number 
of rounds of TTT required to achieve the same impact as an 
additional round of TCT across varying assumptions about spa-
tial heterogeneity in transmissibility, mixing between ham-
lets, and the initial number of rounds of TCT (1 to 3). When the 
overall prevalence of yaws (both active and latent infection 
combined) was the outcome of interest, this model demon-
strated that multiple rounds of TTT were likely to be required 
to match the impact of a single additional round of TCT 
even when TTT was administered to the entire population of 
a village.
Yaws surveillance
The currently proposed goal for yaws is eradication by 2030, 
defined as interruption of transmission (absence of new cases) 
globally. This raises questions regarding the proposed strat-
egy and means of certifying elimination. Recent regression 
modelling estimates that, for 66 out of the 86 countries whose 
current status is unknown, there is a less than 50% prob-
ability of reporting cases without an active surveillance program 
(Fitzpatrick et al., 2018). Thus this indicates that to ensure 
global eradication by 2030, it is necessary to undertake sur-
veillance in these previously endemic countries. Furthermore, 
surveillance during elimination campaigns is hindered by the 
cross-reactivity of the yaws serological test, so that only children 
can be reliably classed as having latent yaws from the testing. 
We note, however, that it is still the case that adults that 
are serologically negative are not carriers of latent yaws, and 
therefore tests in adults may still be of use.
Where are there risks that need to be mitigated to 
achieve the goal?
The primary risk for yaws, is a general lack of political 
commitment and funding for yaws eradication. This lack of 
community buy-in and serious questions regarding whether 
yaws eradication should be a priority presents a serious risk to 
program success. The possibility of achieving eradication by 
2030 is also highly dependent on what proportion of previously- 
endemic countries still contain cases of yaws as this will have 
significant implications for the scale of intervention required 
globally. In recent years two countries (Liberia and the 
Philippines) have been found to still be endemic (World Health 
Organization, 2018) highlighting the possibility that the number 
of countries requiring interventions for yaws eradication 
may grow substantially as surveillance is undertaken in a wider 
range of settings.
Systematic non-participation in both TCT and TTT may pose 
a hindrance to elimination. No measure has been made in this 
disease; however, previous modelling work shows that in mass 
drug administration campaigns systematic non-participation 
can have a significant effect, particularly when levels of rein-
fection are low (Dyson et al., 2017). In the wider literature 
on MDA in infectious diseases, correlations between rounds 
were found of between 0.28 and 0.54 (Dyson et al., 2017). 
Future modelling work could determine the effect of systematic 
non-participation on the outcome of elimination campaigns for 
yaws. In addition, drug resistance represents a risk to implemen-
tation of TCT and TTT with azithromycin. Resistance has been 
reported in Papua New Guinea in the context of a yaws eradi-
cation study (Mitjà et al., 2018). Finally, as with many NTDs, 
it is important to require sufficient coverage of surveillance 
efforts to be sure that zero cases found represents interrup-
tion of transmission. As discussed above, in many countries it 
is unlikely that passive surveillance will result in reporting of 
new cases (Fitzpatrick et al., 2018).
Future work
Current modelling work is limited by the availability of suit-
able datasets, since a model fitted to data from a specific geo-
graphical location may not be directly applicable in another 
setting. In particular high-quality survey data is lacking 
from West and Central Africa, the region of the world where 
the second most cases arise (after the Pacific, where most cur-
rent modelling data is derived from). It is this lack of set-
ting-specific data that hinders country-specific predictions. In 
addition, given suitable data, modelling could also be under-
taken that includes definitions of “contact” for TTT other than 
household contacts. For example, modelling school based 
contacts requires data in which the schools attended by 
children is included.
Other potential extensions include age-prevalence model-
ling, to determine whether serological testing in children aged 
1–5 is necessary and sufficient for determining the interrup-
tion of transmission. Along with spatial modelling to assess 
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clustering, these models can be used to consider surveillance 
strategies. So far, most yaws modelling has focused on TCT 
and TTT, and not ongoing surveillance. Additional research 
should consider in greater depth ongoing community-based 
surveillance and the implications of treating suspected cases 
and, possibly, their contacts. Such research would shed light 
on the extent to which rapid identification of symptomatic 
cases should be a programmatic priority.
The dynamics of latent infection (i.e. the period during which 
infected individuals are at risk of reactivating and devel-
oping symptomatic and infectious yaws) deserves further 
study. Future modeling studies should further explore the 
extent to which results are sensitive to assumptions about 
the duration of latent infections. Most yaws models have 
implicitly assumed that the duration of latent infection is expo-
nentially distributed. This distributional assumption deserves 
further study. Measuring the duration and distribution of 
latent infection is challenging, in part because it would be 
unethical to prospectively follow-up untreated yaws patients. As a 
first step, models could be used to explore what sort of data would 
be required to indirectly infer the dynamics of latent infection.
Finally, further modelling may be undertaken to answer the 
question: “would achieving >90% coverage in children even if 
the overall population coverage is <90% be sufficient to inter-
rupt transmission?” This work would need additional data 
regarding the amount of transmission between children and 
adults, which is difficult to obtain due to the problems with 
serological testing in adults. Without such data we could still 
ask the question: if adult transmission is very frequent we 
wouldn’t expect focusing coverage on children to interrupt 
transmission - how much rarer does it need to be for this strat-
egy to be successful? Further economic modelling could also be 
undertaken given more data regarding the costs of TTT.
Data availability
No data are associated with this article.
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